JRCT ID: jRCT2080224762
Registered date:03/07/2019
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 29/07/2019 |
Target sample size | 924 |
Countries of recruitment | Japan,Asia except Japan,North America,South America,Europe,null |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : dupilumab Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy safety safety exploratory |
Key inclusion & exclusion criteria
Age minimum | >= 40age old |
---|---|
Age maximum | <= 80age old |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03930732,2018-001953-28,JapicCTI-194839 |
Contact
Public contact | |
Name | |
Address | |
Telephone | +81-3-6301-3670 |
clinical-trials-jp@sanofi.com | |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | +81-3-6301-3670 |
clinical-trials-jp@sanofi.com | |
Affiliation |